Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04508413 · ClinicalTrials.gov registry record · NA
A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function
A NA study, sponsored by Kaleido Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT04508413 is a NA study that has completed, run by Kaleido Biosciences. The registered enrollment target is 12 participants.
The verdict
NCT04508413, a NA study, has completed, sponsored by Kaleido Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
This exploratory, open-label clinical study aims to explore the effects of KB295, a novel glycan, on adult patients with ulcerative colitis (UC) presenting with mild-to-moderate UC symptoms
Interventions
- OTHER KB295
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2021-11-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04508413
The ClinicalTrials.gov registry entry for NCT04508413 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaleido Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KB295 is the first listed.
NCT04508413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04508413 about?
NCT04508413 is a clinical study titled "A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function". This exploratory, open-label clinical study aims to explore the effects of KB295, a novel glycan, on adult patients with ulcerative colitis (UC) presenting with mild-to-moderate UC symptoms
What is the current status of trial NCT04508413?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2020-08-12. Estimated completion is 2021-11-29.
What interventions are being tested in trial NCT04508413?
The interventions under investigation include: KB295 (OTHER).
Who is sponsoring clinical trial NCT04508413?
This trial is sponsored by Kaleido Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.